Marvell Technology, Inc. (MRVL)

According to NextEarningsDate.com, the Marvell Tech next earnings date is projected to be 8/28 after the close, with earnings estimates of $0.61/share on $2.01 Billion of revenue. Looking back, the recent Marvell Tech earnings history looks like this:

Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China National Intellectual Property Administration (CNIPA) has granted patent number ZL202180020893.4, titled "Purine Compounds for Treating Disorders". The patent covers the composition of matter for Marvel's lead asset, MB-204.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

SANTA CLARA, Calif. , Aug. 18, 2025 /PRNewswire/ -- Marvell Technology, Inc. (NASDAQ: MRVL), a leader in data infrastructure semiconductor solutions, today announced that Microsoft has selected the Marvell ®  LiquidSecurity ®  family of hardware security modules (HSMs) for Microsoft Azure Cloud HSM.

Marvell Technology (MRVL -2.28%) just posted 180% profit growth and 63% higher revenue. With deep ties to Amazon and Nvidia, and a 98% upside, this artificial intelligence infrastructure play is flying under the radar.

Zacks.com users have recently been watching Marvell (MRVL) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Marvell Technology's surging Data Center revenues are fueled by custom AI XPUs, optics advances, and cutting-edge chip packaging innovations.

Chip stocks trend as profit-taking meets massive AI spending plans, led by $250B+ investments from Meta, Microsoft, and Google.

SANTA CLARA, Calif. , Aug. 14, 2025 /PRNewswire/ -- Marvell Technology, Inc.  (NASDAQ: MRVL), a leader in data infrastructure semiconductor solutions, today announced it has completed the sale of its Automotive Ethernet business to Infineon Technologies AG ("Infineon") for $2.5 billion in an all-cash transaction.

Astera Labs gains edge over Marvell Technology with AI-focused innovations, partnerships, and market momentum in next-generation connectivity.

Marvell is a leading fabless chip designer, benefiting from surging data center demand, especially in AI-driven applications. Key growth catalysts include major supply agreements with AWS and Microsoft, positioning Marvell alongside industry giants like Broadcom. The company is improving profitability through cost-cutting and margin expansion, while hyperscaler concentration and trade risks remain watchpoints.

Every month it seems like one company or another announces it is increasing its budget for artificial intelligence (AI) data centers. Last month, Alphabet released plans for $85 billion in capital expenditures (capex) this year, up from its original 2025 outlook of $75 billion.

Massive Revenue Projections: A recent Wall Street estimate suggests that Marvell's deal with Microsoft could generate $2.4 billion in revenue by 2026 and $10 to $12 billion by 2027, potentially exceeding the company's overall revenue expectations with just one custom chip deal.

Marvell is a value Buy in the AI-driven semiconductor space, with robust growth prospects and relative undervaluation versus peers. Strong Q1 FY2026 results and guidance, driven by AI and data center demand, support a multi-year high growth thesis for Marvell. Key risks include heavy China exposure and geopolitical uncertainties, which are already factored into current valuations.

I reiterate my buy rating on Marvell, raising my price target to $108, driven by strong AI/data center demand and robust earnings growth. Marvell's Q1 results beat expectations, with data center revenue surging and management guiding for continued sales growth, especially in ASICs. Valuation remains attractive with a PEG below 1.5x and EPS compounding above 20%, supported by bullish analyst revisions and solid free cash flow.

Calgary, Alberta--(Newsfile Corp. - August 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 142,987 deferred share units ("DSUs") to two of Marvel's directors, in lieu of cash payment for directors' fees. The DSUs will all vest on July 31, 2026.